Cannasat Therapeutics Retains Leading Investor Relations Firm
MarketWire, November 8, 2021
TORONTO – Cannasat Therapeutics (TSXV: CTH) (the "Company"), today announced that it has retained The Equicom Group ("Equicom") to provide the Company with strategic investor relations and financial communications services.
Equicom provides strategic communications services to approximately 100 public companies across a diverse range of industries. Under the terms of the agreement, Cannasat will pay Equicom a monthly retainer fee of $5,000 for professional services. The initial contract term is 12 months. Neither Equicom nor any of its principals has an ownership interest, directly or indirectly, in the Company or its securities, and the Company has not granted Equicom or its principals any right to acquire such an interest.
About Cannasat Therapeutics
Founded in 2004, Cannasat is an early stage pharmaceutical research and development company. Cannasat is developing cannabinoid-based pharmaceutical products using proprietary formulation and drug delivery technologies. Cannabinoids have broad therapeutic applications which are believed to include the treatment of neuropathic pain, chronic pain, depression, anxiety and movement disorders. More information about Cannasat (TSX-V: CTH) is available at www.cannasat.com.
Contact Information
Cannasat Therapeutics Inc.
Andrew Williams
COO & CFO
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]
www.cannasat.com
The Equicom Group
James Smith
Investor Relations
W: (416) 815-0700 (Ext. 229)
F: (416) 815-0080
[email protected]
www.equicomgroup.com
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.
